AI Agents Explained: Could Autonomous Software Create the Next Big Computing Boom?

Educational research only — not investment advice.

AI agents could become the next major stage of the artificial-intelligence boom.

Chatbots mainly respond when a user asks a question. AI agents go further: they can receive a goal, decide what steps are needed, use software tools and perform multiple tasks with less human intervention.

That difference could have major implications for software companies, cloud providers, data centers and AI chip demand.

What Is an AI Agent?

An AI agent is software designed to pursue a task rather than simply generate an answer.

For example, instead of asking an AI:

“Find some flights to New York.”

An AI agent could potentially:

search flights → compare prices → check your calendar → prepare an itinerary → request approval

In business, agents could perform tasks such as:

  • analyzing company data
  • writing and testing code
  • monitoring cybersecurity
  • preparing reports
  • handling customer requests
  • managing repetitive workflows

The important feature is that the software can complete a sequence of actions.

Why Are AI Agents Becoming Important?

The technology is already moving beyond simple experimentation.

Anthropic said in September that Claude was leading about 26% of work involved in developing its next AI models, while around 30,000 AI agents were operating on its internal platform.

Anthropic stressed that these systems still operate under human supervision rather than independently.

That distinction matters.

Today’s agents are not fully autonomous digital employees.

But they are becoming capable of completing longer and more complex tasks.

Why Could Agents Create More Computing Demand?

A chatbot may process one request and produce one answer.

An agent can perform dozens or hundreds of steps.

It may repeatedly:

read information → reason → use a tool → check the result → make another decision

Each step consumes computing resources.

If millions of businesses eventually deploy agents that operate continuously, AI usage could rise far faster than the number of human users.

Huawei has projected that autonomous agents could eventually account for more than 90% of global AI token traffic by 2035, although that is a long-term industry forecast rather than a certainty.

The broader mechanism is straightforward:

more AI agents → more AI requests → more computing → more data-center demand

Why This Matters for AI Chips

More agent activity could support demand for the infrastructure that runs AI models.

That includes:

  • GPUs and AI accelerators
  • advanced memory
  • networking equipment
  • cloud computing
  • data-center capacity
  • electricity and cooling

Demand for computing is already strong enough that cloud provider Nebius recently announced another increase in prices for access to certain Nvidia chips, its second such increase in three months.

AI agents could add another source of demand if they become widely deployed.

Software Could Benefit Too

The first phase of the AI boom heavily rewarded companies supplying infrastructure.

Agents could shift more attention toward software monetization.

Companies may eventually charge businesses for agents that handle:

  • accounting workflows
  • sales processes
  • coding
  • research
  • customer service
  • cybersecurity
  • administration

If agents save companies meaningful amounts of employee time, businesses may be willing to pay recurring subscription or usage fees.

That could create a new source of revenue for software companies.

But Productivity Still Has to Appear

The biggest uncertainty is whether AI agents actually generate enough economic value.

AI adoption has grown quickly, but broad productivity gains have so far been less dramatic than some early forecasts suggested. Reuters Breakingviews noted that AI was already being used in about 44% of U.S. workplaces by May 2026, while economy-wide productivity improvements remained relatively modest.

Companies still need to redesign workflows, train employees and integrate AI into existing systems.

So the real question is not:

“Can an AI agent perform a task?”

It is:

“Can it perform that task reliably enough and cheaply enough to create measurable value?”

What Are the Risks?

Greater autonomy also creates new problems.

Agents need access to software, data and sometimes external systems to perform useful work.

That creates risks involving:

  • incorrect actions
  • cybersecurity
  • sensitive information
  • unreliable decisions
  • excessive computing costs
  • lack of human oversight

Companies developing advanced agents are therefore adding monitoring and safety controls alongside greater autonomy. Anthropic, for example, says actions by its internal agents are screened before execution.

What Would Confirm an AI-Agent Boom?

Several signals would matter more than headlines.

Enterprise adoption: Are companies deploying agents beyond small experiments?

Revenue: Are customers paying meaningfully for agent-based products?

Compute usage: Does agent adoption materially increase cloud and GPU demand?

Productivity: Are businesses actually saving time or reducing costs?

Reliability: Can agents complete long tasks without frequent human correction?

If those metrics improve together, AI agents could become an important second phase of the AI investment cycle.

What Should Investors Watch?

The most useful indicators are AI-agent adoption, cloud-computing demand, software revenue, GPU utilization, data-center spending and enterprise productivity.

The key idea is simple:

AI agents could turn AI from something humans occasionally consult into software that works continuously in the background.

If that transition happens at scale, the computing requirements could be enormous.

But the size of the opportunity will ultimately depend on whether agents create enough real economic value to justify the infrastructure behind them.

Analyze Technology Trends With TradingSimuLab

TradingSimuLab’s Macro and market-analysis tools help users study changing investment themes, market regimes and risk conditions rather than relying on hype around a single technology.

For more quantitative market research and educational trading tools, sign up to TradingSimuLab.

TradingSimuLab is for educational and research purposes only and does not provide investment advice.

Continue exploring TradingSimuLab.

  • Software Stocks: Can AI Turn From a Threat Into a Revenue Opportunity?

    If artificial intelligence could build applications, automate workflows and let companies create their own tools, why keep paying large subscription fees to traditional software providers? That fear hit companies such as Salesforce and ServiceNow hard. Now the story may be changing. Salesforce recently reported its strongest growth in net new annual order value in four…

  • AI Training Data: Is Data Becoming More Valuable Than the Model?

    The AI race is no longer only about building bigger models. Increasingly, it is also about building better data. That shift is visible in the rise of Snorkel AI, which recently raised $350 million at a $3.5 billion valuation as demand grows for specialized datasets, reinforcement-learning environments and expert-generated training material. Its annualized revenue has…

  • Why Shipping Costs Can Move Oil Prices Even When Supply Is Available

    Oil prices can rise even when plenty of crude exists. One reason is often overlooked: shipping costs. Recent Venezuelan crude trades show the problem clearly. Reuters reported that tanker costs from Venezuela’s Jose port to the U.S. Gulf had risen to roughly $3.5 million per Aframax voyage, forcing traders to demand deeper discounts on the…

  • Currency Intervention Explained: Can Governments Stop a Falling Currency?

    A currency can keep falling even after interest rates rise. That is exactly why currency intervention periodically returns to the spotlight. The Japanese yen recently traded around 157.5 per U.S. dollar despite the Bank of Japan raising its policy rate to 1.25%. Markets remain alert to another possible intervention after reports of Japanese authorities checking…

  • India Stock Market: Why Global Banks Are Rushing Back In

    Global banks are paying closer attention to India’s capital markets. HSBC is preparing to re-enter India’s equity-broking business after more than a decade away, rebuilding its equities platform as IPO activity and demand from wealthy investors expand. Reuters reports that the bank is hiring for cash-equities and institutional-broking roles and may also relaunch retail broking…

  • Solar Stocks India: Can Domestic Panel Makers Compete With China?

    India is building a much larger domestic solar manufacturing industry. One of the clearest signs is Avaada Electro, which is preparing a major IPO as it expands solar-cell and module production. The company currently has about 8.5 GW of module capacity and is targeting 13.6 GW, alongside major expansion in solar-cell manufacturing. For investors watching…

  • Japan Bond Yields: Why Higher Rates Can Move Global Markets

    For decades, Japanese investors sent enormous amounts of money overseas in search of higher returns. That may be starting to change. Japan bond yields recently pushed above 3% on the 10-year government bond, the highest level since 1996. At the same time, Japanese investors have begun reducing some overseas bond exposure as domestic bonds become…

  • Corporate Governance Explained: Why Shareholder Rights Matter as Much as Earnings

    Investors spend enormous amounts of time studying revenue, margins and earnings. But sometimes the biggest risk sits somewhere else: Who actually controls the company? A recent dispute inside India’s Tata Group has brought corporate governance back into focus. Tata Sons and its controlling shareholder, Tata Trusts, have clashed over board authority, the reappointment of chairman…

  • Pharmaceutical Stocks: Why Europe Is Losing Ground in Drug Research

    Europe has some of the world’s largest pharmaceutical companies. But an increasing share of global drug research is happening elsewhere. European drugmakers say the region’s share of global pharmaceutical R&D has fallen from about 43% to 31%, while its share of commercial clinical trials has dropped to roughly 9% over the past decade. Industry leaders…